Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib (ARQ 197) in Second-Line Hepatocellular Carcinoma
BURLINGTON, Mass. and PARSIPPANY, N.J., March 22, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) and Daiichi Sankyo today announced that the independent data monitoring committee (DMC) of the METIV-HCC study conducted the planned interim assessment and it was determined the trial will continue to its final analysis.
Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib (ARQ 197) in Second-Line Hepatocellular Carcinoma
BURLINGTON, Mass. and PARSIPPANY, N.J., March 22, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) and Daiichi Sankyo today announced that the independent data monitoring committee (DMC) of the METIV-HCC study conducted the planned interim assessment and it was determined the trial will continue to its final analysis.
http://files.shareholder.com/downloads/ARQL/1155639440x0x882287/84DDD033-9DCA-46B6-9556-D4E90448754B/METIV-HCC_Interim_Analysis_Press_Release__cs.pdf